NCT01461447已完成1 期
Safety and Immunogenicity Following Further Boosting With HIV-1 MVA-CMDR Vaccine to HIVIS03 Volunteers Who Were Primed With HIV-1 DNA Low Dose Intradermally or 'Standard' Dose Intramuscularly and Boosted With MVA-CMDR Vaccine
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Safety assessed by the number of solicited and non solicited adverse events following immunization
研究概览
简要总结
The purpose of the study is to determine the safety and immunogenecity of a third MVA in the HIVIS 03 volunteers who have received 3 HIVIS DNA vaccines followed by boosting with 2 MVA vaccines.
The investigators postulate that the Immune responses that were observed in the HIVIS 03 trial are likely to wane over time. To date it is unknown how these responses should best be maintained. In this study the investigators seek to boost immune responses, especially the antibody responses induced by the second MVA boost.
Since the HIV specific antibodies were induced only after the second MVA injection, it is hypothesized that a 3rd MVA will give rise to even higher and sustained antibody titers.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Have completed the HIVIS03/TaMoVac01 WP1 protocol and received the active vaccine
- •Willing to undergo counseling and HIV testing
- •Are not infected by HIV infection as indicated by a negative PCR reaction against HIV.
- •Able to give informed consent
- •Resident in Dar es Salaam, and willing to remain so for the duration of the study
- •At low risk of HIV infection, defined as the absence of an identifiable risk factor/ behavior:
- •sexual partner with HIV
- •sexual partner with unknown HIV serostatus who is also unwilling to use protective condoms consistently in all sexual relations
- •sexual partner is known to be at high risk for HIV
- •more than one sexual partner in the last 6 months.
- •history of being an alcoholic [as medically defined or more than 35 units /week]
- •History of STI within past 6 months.
- •Verbal assurances that adequate birth control measures are used not to conceive/father a child during the study and up to 4 months after the 3rd MVA vaccine injection
- •Have a negative urinary pregnancy test for females
- •ECG findings that neither pose a risk for the vaccination nor preclude evaluation of peri/myocarditis.
- •Be willing to practice safe sex for the duration of the study to avoid sexually transmitted infections including HIV.
- •Good health as determined by medical history, physical examination, clinical judgment and by key laboratory parameters
- •Reference ranges will be in accordance with data generated at MUHAS for hematology values, and biochemical parameters. Exclusion by presence of Diabetes mellitus will be based on the WHO cut-off value of a Fasting Blood Glucose >7.8 mmol/l
- •No grade 1 or higher routine laboratory parameters (see section on appendix 3 DAIDS chart for Definitions). Hence lab parameters have to be as follows:
- •Hb >10.5g/dl
- •White blood cell count >1,300/mm3
- •Lymphocytes >1.0/ mm3
- •Platelets >120,000/ mm3
- •CD4 >400cells/ mm3
- •Random Blood Glucose 2.5-7.0 mmol/L; if elevated, then a Fasting Blood Glucose <7.8 mmol/l
- •Bilirubin <1.25 x uln
- •ALT <1.25 x uln
- •Creatinine <1.25 x uln
- •Urine dipstick for protein and blood: negative or trace. (If either is ≥ 1+, obtain complete urinalysis (UA). If microscopic UA confirms evidence of hematuria or if proteinuria ≥ 1+, the volunteer is ineligible).
排除标准
- •Active tuberculosis or other systemic infectious process elicited by review of systems, physical examination and laboratory detection. Such as detection of Hepatitis B surface antigen, or active syphilis.
- •Have a history of immunodeficiency, chronic illness requiring continuous or frequent medical intervention
- •Autoimmune disease by history and physical examination.
- •Severe eczema
- •Have history of psychiatric, medical and/or substance abuse problems during the past 6 months that the investigator believes would adversely affect the volunteer's ability to participate in the trial.
- •History of grand-mal epilepsy, or currently taking anti-epileptics
- •Have received blood or blood products or immunoglobulins in the past 3 months.
- •Are receiving immunosuppressive therapy such as systemic corticosteroids or cancer chemotherapy.
- •Have used experimental therapeutic agents within 30 days of study entry.
- •Have received any live, attenuated vaccine within 60 days of study entry. {NOTE: Medically indicated subunit or killed vaccines (e.g., Hepatitis A or Hepatitis B) are not exclusionary but should be given at least 2 weeks before or after HIV immunization to avoid potential confusion of adverse reactions}.
- •History of severe local or general reaction to vaccination defined as:
- •Local: Extensive, indurated redness and swelling involving most of the major circumference of the arm, not resolving within 72 hours
- •General: Fever >= 39.5 0C within 48 hours; anaphylaxis; bronchospasm; laryngeal oedema; collapse; convulsions or encephalopathy within 72 hours
- •Are lactating mothers
- •Are study site employees who are involved in the protocol and may have direct access to the immunogenicity results
- •Unlikely to comply with protocol as judged by the principal investigator or her designate.
结局指标
主要结局
Safety assessed by the number of solicited and non solicited adverse events following immunization
时间窗: 1 month after vaccination
Proportion of volunteers with humoral and cellular immune responses elicited by 2 different immunization schedules (id or im DNA priming) prior to MVA boosting
时间窗: 1 month after vaccination
次要结局
- Number of staff trained and able to conduct HIV-related vaccine studies at MUHAS.(Two months)
研究者
Patricia Jane Munseri
MD
Muhimbili University of Health and Allied Sciences
研究点 (1)
Loading locations...
相似试验
已完成
2 期
FSME IMMUN NEW Follow-up to Study 199 in Children Aged 1 to 6 YearsEncephalitis, Tick-borneNCT00161850Pfizer615
已完成
2 期
FSME IMMUN NEW Follow-up to Study 205 in Children Aged 6 to 16 YearsEncephalitis, Tick-borneNCT00161889Pfizer615
Unknown
4 期
Immunogenicity and Safety of a Third Dose and Immune Persistence of BBIBP-Corv Vaccine in People With HIV InfectedCOVID-19HIV InfectionsNCT05105295China National Biotec Group Company Limited400
已完成
2 期
Evaluation of the Immune Response of a HIV Candidate Vaccine After Administration of One Chloroquine DoseAIDSNCT00972725GlaxoSmithKline28
已完成
3 期
Study of a Booster Dose of IMOJEV® One Year After Primary Immunization in Healthy Children in South KoreaJapanese EncephalitisNCT01900444Sanofi Pasteur, a Sanofi Company119